Mayne Pharma Appoints New President - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mayne Pharma Appoints New President



Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma’s existing business operations and overseeing the expansion of Mayne Pharma’s pharmaceutical products division. In addition, Cross will manage the continued growth of contract pharmaceutical services as provided by Mayne Pharma’s subsidiary, Metrics.

Previously, Cross served as Mayne Pharma’s vice-president of business and corporate development, and played a role in the global commercialization of the company’s SUBACAP anti-fungal product. He has been involved inintegrating Metrics with Mayne Pharma, and in executing the company’s business strategy in Australia and the US. Cross headed marketing efforts in the Asia Pacific region for Hospira and led Hospira’s commercial operations in China, Hong Kong, and Taiwan. Prior to that, Cross worked for six years with Mayne Pharma Limited in Europe and Australia, and eight years with F.H. Faulding & Co. Limited.

Cross succeeds Phil Hodges, who founded Metrics and currently serves on the board of directors of Mayne Pharma Group Limited.

Source: Mayne Pharma Group Limited

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here